of sample containing multiple components (pBR322/MspI plasmid digest; Sigma) in even-numbered wells (chiploading protocol D). No interwell contamination was observed during chip analysis. Thus, the improved consistency of signal quantification observed was not attributable to interwell contamination but rather to enhanced intrawell sample mixing. Chip-loading protocol D was used for all subsequent experiments.
To evaluate the ability of the Bioanalyzer to measure absolute concentrations, concentrated eNOS PCR product (ϳ40 ng/L) was diluted in Tris-EDTA buffer to yield solutions containing 2.6, 5.1, 13.0, and 28.4 ng/L. Each sample was loaded twice on each chip, with one sample being loaded in wells 1-6 and a duplicate sample being loaded into wells 7-12. Concentration values generated by the Bioanalyzer differed from concentration values obtained spectrophotometrically by 6 -16%. Well-to-well and chip-to-chip results differed by similar amounts. DNA sizing results were found to be independent of the cDNA concentration.
To evaluate the ability of the Bioanalyzer to size samples containing multiple DNA fragments, commercially available plasmid digests were analyzed. To reduce the concentration of DNA fragments Ͻ100 bp in size, plasmid digests were spin-purified using the QIAquick PCR purification method, and samples were eluted in 1ϫ Tris-EDTA buffer and diluted to yield appropriate concentrations for analysis. pUC18/MspI digest (Sigma) samples were loaded into wells 1, 4, 7, and 10; X174 RF DNA/ HaeIII fragments (Gibco) samples were loaded into wells 2, 5, 8, and 11; DNA/EcoRI marker (Promega) samples were loaded into wells 3, 6, 9, and 12. This experiment was performed twice on each of 2 successive days. Table  1 , D and E, shows sizing and signal quantification results, respectively, for X174 RF DNA/HaeIII. The CV for DNA sizing of fragments was Յ2.1%, whereas the CV for DNA signal quantification was Յ6.7%. Similar CV values were observed for pUC18/MspI digest with respect to sizing and quantification. CVs for DNA sizing and quantification were ϳ8% and 7%, respectively, for DNA/EcoRI markers. Similar results were observed for unpurified plasmid digests.
In summary, we recommend a modification to the manufacturer's protocol for chip loading: namely, gentle pipetting of samples with the marker mixture after loading into the sample wells, followed by vortex-mixing for 1 min at the highest setting, which does not cause liquid loss from the sample wells. Lower concentration DNA fragments may not be detected if poor chip preparation leads to weak sample staining. This is particularly crucial with respect to the manufacturer-supplied molecular size ladder. The Bioanalyzer cannot calculate size and concentration values for the experimental samples if it fails to detect all bands in the ladder. In addition, improper staining of the upper molecular size marker may lead to poor quantification of experimental DNA fragments.
We found the Agilent 2100 Bioanalyzer to be an easyto-use, time-efficient substitute to conventional CE. It was effective at sizing and quantifying multiple DNA frag-ments in a variety of experimental samples, including plasmid digests and PCR samples. This work was supported by grants from the NCI (Grant CA78848-02 to P.W. and L.J.K.) and NIH (Grant P60-HL38632 to P.F.). P.W. and L.J.K. previously were recipients of grant support from Caliper Technology Corporation and were stock holders of and consultants to this company. Hereditary hemochromatosis (HH) is a common autosomal recessive disorder (frequency, 1 in 300 -500 in the Northern European population) characterized by overabsorption of iron with consequent multiorgan failure secondary to iron overload (1, 2 ) . Because early diagnosis and therapy can entirely prevent clinical complications, HH presents a model system for presymptomatic detection at the molecular level. HFE, the disease-causing gene of HH, encodes a 343-amino acid protein with high structural similarity to MHC class I molecules (3, 4 ) . The primary disease-causing mutation is a single G-to-A transition at position 845, encoding a protein with a Cys282Tyr amino acid substitution (3 ) .
Evaluation of a Nucleic Acid-based Cross-Linking Assay to Screen for Hereditary Hemochromatosis in
Current HH genotyping techniques include restriction fragment length polymorphism (RFLP) analysis (5 ) and heteroduplex analysis (6 ), both PCR based. We evaluated a nucleic acid-based test with cross-linkable DNA probes to screen for the Cys282Tyr mutation in a total of 101 presumably healthy blood donors. The assay uses oligonucleotide probes modified with photo-activatable crosslinker molecules (7 ) and has been used to detect the factor V Leiden mutation (8 ) . Two sets of allele-specific crosslinkable DNA probes were prepared that detect either the wild-type or mutant Cys282Tyr gene sequences. Samples prepared from donor blood were assayed with each probe set, and the genotype of each individual was determined by comparison of the fluorescent signals obtained. All blood samples were also assayed by a PCR-RFLP test.
Two capture probes that hybridized preferentially to the wild-type or mutant HFE gene sequence, respectively, were synthesized for the cross-linking assay: (5Ј-3Ј) AX-ATACGTGCCAGGTG and AXATACGTACCAGGTGG (the underlined bases represent the position of the mutation site in the target). The coumarin-based cross-linking nucleotide is denoted as X; both probes were biotinylated at the 3Ј end (8 ) . In addition, 24 reporter probes were synthesized, each containing two fluorescein residues at the 5Ј terminus and a cross-linker molecule in place of a nucleotide one position from the 3Ј terminus, the 5Ј terminus, or both. The reporter probes were designed from HFE gene sequence flanking the mutation, corresponding to the following nucleotide positions (9 ): 6443-6462, 6472-6493, 6495-6518, 6574 -6593, 6597-6618, 6632-6653, 6661-6682, 6686 -6707, 6716 -6739, 6780 -6799, 6801-6822, 6838 -6861, 6877-6900, 6905-6928, 6951-6973, 6984 -7006, 7060 -7083, 7089 -7108, 7128 -7151, 7163-7186, 7208 -7231, 7235-7256, 7301-7322, and 7381-7402.
Blood specimens were obtained from 101 blood donors with informed consent under an institutional review board-approved protocol (University of Cologne). Leukocytes were isolated from blood samples as described (8 ), resuspended in leukocyte lysis reagent (0.28 mol/L NaOH), and either boiled at 100°C for 30 min immediately before the assay or stored at Ϫ20°C for up to 14 days before boiling.
Processed samples were placed into two wells each of a 96-well polypropylene microtiter plate. Each assay plate also contained four negative controls (leukocyte lysis reagent that had not been boiled) and two positive controls (50 amol/well of a PCR amplicon covering the assay locus amplified from a Cys282Tyr and wild-type heterozygote in leukocyte lysis reagent that had not been boiled). Two different probe solutions were prepared, each containing the same set of 24 reporter probes and 1 of the 2 allele-specific capture probes. Aliquots of each probe solution were added to one of each pair of sample wells, as well as two negative and one positive control wells. Neutralization of the solutions, photo cross-linking, and addition of the streptavidin-coated magnetic beads have been described (8 ) . The beads were then washed twice with wash reagent (0.15 mol/L NaCl, 0.015 mol/L sodium citrate, 1 mL/L Tween-20). The beads were incubated in the presence of anti-fluorescein antibody-alkaline phosphatase conjugate (Dako), washed four times, and resuspended in Attophos TM (Promega) as described (8 ) .
The fluorescence signal was determined by reading the plate in a microplate fluorometer (Packard Instrument).
Genomic DNA was extracted from whole blood by the QIAquick Blood reagent set (QIAGEN). A sequence flanking the variant codon 282 was amplified by PCR (DyNAzyme PCR reagent set; Biometra), and the amplicons were digested with RsaI (Roche), size-fractionated by agarose gel electrophoresis, and genotyped as described (5 ) .
Determination of the genotype of an individual with the cross-linking assay was based on the relative signals obtained with the two allele-specific capture probe preparations. The net sample signal (NSS) was derived for each sample and each probe set by subtracting the mean of the negative control values from the sample signal. The NSS ratio was defined for each sample as the NSS for the mutation divided by the NSS for the wild type. The NSS ratio intervals that define a particular genotype were set before the donor samples were tested by assaying PCR amplicons derived from individuals who were wild type, heterozygous, or mutant homozygous for the Cys282Tyr allele (20 determinations for each genotype). These experiments yielded the following mean NSS ratios: wild type, 0.05 (range, 0.01-0.45); heterozygous, 1.22 (range, 0.95-2.15); and mutant homozygous, 6.13 (range, 2.95-15.00). On the basis of these results, the following NSS ratio intervals were used to assign a sample genotype: wild type, NSS ratio ϭ 0 -0.75; heterozygous, NSS ratio ϭ 0.76 -2.5; and homozygous mutant, NSS ratio Ͼ2.5.
The sample data fell into two groups (Fig. 1 ). The first group of 93 samples had NSS ratios of 0.12-0.66 (mean ϭ 0.36; SD ϭ 0.11) and was assigned a wild-type genotype. The second group (eight samples) had NSS ratios of 1.02-1.55 (mean ϭ 1.30; SD ϭ 0.18), compatible with heterozygosity. No individuals homozygous for the Cys282Tyr mutation were identified. To validate the method for detection of the homozygous mutant genotype, the assay was performed on a blood sample from a known homozygote. The NSS ratios for this individual, in two evaluations, were 9.1 and 7.4, within the predicted range.
The results of PCR-RFLP testing were in complete agreement with those obtained with the cross-linking assay for all 101 samples.
The cross-linking assay has several advantages. It allows detection of the Cys282Tyr mutation without the laborious steps of DNA purification, PCR, and RFLP analysis, and it eliminates problems of sample inhibition of polymerases and sample contamination by amplicons. An additional advantage is the large-scale simultaneous processing of DNA samples, using the microtiter plate format. With automated detection, the cross-linking assay can be finished within 4 h.
Further work is needed to fully define the set of NSS ratio ranges that determine the three genotypes. Data from the blood sample assays showed wider variation among samples of the same genotype than was seen with the PCR samples. Presumably, this indicates that signal intensity is influenced by factors such as the efficiency of the overall sample preparation procedure and variation in blood volume and leukocyte concentration. Further sample data will allow us to set finer intervals for genotype assignment and to set "gray zone" values for repeat testing.
Large-scale, presymptomatic screening of blood donors for the Cys282Tyr mutation could identify individuals at risk for HH, who are then candidates for prophylactic phlebotomy, which increases the life expectancy to that of the general population. If such a screening regimen was to be implemented, the tests needed to perform genotype analysis will have to be accurate, inexpensive, and automatable. The cross-linking assay used here is an efficient, simple, and rapid method of genotyping HFE mutations that, with automation, would be suitable for routine genetic analysis in a large-scale manner.
